Pharmaceutical Supply for Nuclear Power Corporation of India Limited

Nuclear Power Corporation of India Limited, under the aegis of the Department of Atomic Energy and the Ministry of State Name PMO, is issuing an invitation to tender for the supply of essential pharmaceutical products. This tender, identified by Bid Number GEM/2026/B/8003450, is scheduled to commence on October 16, 2026, at 4:15 PM and will conclude on November 6, 2026, at 5:00 PM. The Bill of Quantities (BOQ) encompasses a diverse range of medicines, specifically categorized under "CAPSULE LIPASE AMYLASE PROTEASE and other medicines," with a total quantity of 29,800 units. The specific items required, with further details provided in an attached document, include VAPO CAPSULE EUCALYPTOL (Bid Item No. 1), SOLUTION SALBUTAMOL (Bid Item No. 2), TABLET MONTELUKAST (Bid Item No. 3), SYRUP LEVOCETIRIZINE (Bid Item No. 4), TABLET EBASTINE (Bid Item No. 5), RESPULES BUDESONIDE (Bid Item No. 6), INJECTION PHENYTOIN SODIUM (Bid Item No. 7), and BOTTLE DEXTROSE (Bid Item No. 8), along with INJECTION TT (Bid Item No. 10). The procurement effort is being managed by the Office in Rajasthan, and potential suppliers are encouraged to review the attached documentation thoroughly for comprehensive specifications and requirements.